.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
UBS
Julphar
Argus Health
Deloitte
Moodys
US Army
Merck
Fuji
Colorcon

Generated: June 28, 2017

DrugPatentWatch Database Preview

LEVORPHANOL TARTRATE Drug Profile

« Back to Dashboard

What is the patent landscape for Levorphanol Tartrate, and when can generic versions of Levorphanol Tartrate launch?

Levorphanol Tartrate is a drug marketed by Sentynl Theraps Inc and is included in one NDA.

The generic ingredient in LEVORPHANOL TARTRATE is levorphanol tartrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the levorphanol tartrate profile page.

Summary for Tradename: LEVORPHANOL TARTRATE

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Clinical Trials: see list137
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LEVORPHANOL TARTRATE at DailyMed

Pharmacology for Tradename: LEVORPHANOL TARTRATE

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sentynl Theraps Inc
LEVORPHANOL TARTRATE
levorphanol tartrate
TABLET;ORAL074278-001Mar 31, 2000RXNoYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Merck
Argus Health
US Army
Colorcon
Covington
Boehringer Ingelheim
Teva
Daiichi Sankyo
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot